Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: PTC THERAPEUTICS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: PTC THERAPEUTICS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REZOLUTE, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Disease state awareness.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REZOLUTE, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · RR
Source: Senate LDA
| BICYCLE THERAPEUTICS |
| 2 |
| 2026 |
| MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) | 2 | 2026 |
| NATERA, INC. | 2 | 2026 |
| REZOLUTE, INC. | 2 | 2026 |
| UNIVERSITY OF LOUISVILLE HEALTH | 2 | 2026 |
| RARE DISEASE COMPANY COALITION | 1 | 2025 |
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Coverage and reimbursement for innovative lab-developed tests. H.R.5269: RESULTS Act.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Patients Deserve Price Tags Act
Client: ERISA INDUSTRY COMMITTEE (ERIC) · Firm: LMH STRATEGIC SOLUTIONS
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.
Patients Deserve Price Tags Act
Client: ERISA INDUSTRY COMMITTEE (ERIC) · Firm: LMH STRATEGIC SOLUTIONS
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: PTC THERAPEUTICS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: PTC THERAPEUTICS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: PTC THERAPEUTICS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV.
Give Kids a Chance Act of 2025
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: IONIS PHARMACEUTICALS, INC. · Firm: LMH STRATEGIC SOLUTIONS
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: STEALTH BIOTHERAPEUTICS INC. · Firm: LMH STRATEGIC SOLUTIONS
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Disease state awareness.
UNIVERSITY OF LOUISVILLE HEALTH via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Medicaid State-Directed Payments and Intergovernmental Transfers.
STEALTH BIOTHERAPEUTICS INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROPACE, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATERA, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Coverage and reimbursement for innovative lab-developed tests. H.R.5269: RESULTS Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IONIS PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERISA INDUSTRY COMMITTEE (ERIC) via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · Q2
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATERA, INC. via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · RR
Coverage and reimbursement for innovative lab-developed tests.
UNIVERSITY OF LOUISVILLE HEALTH via LMH STRATEGIC SOLUTIONS
2026 · second_quarter · RR
Medicaid State-Directed Payments and Intergovernmental Transfers.
MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
General Medicare and Medicaid Issues.
Prescription drug payment reform. Pharmaceutical Supply Chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BICYCLE THERAPEUTICS via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STEALTH BIOTHERAPEUTICS INC. via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS, INC. via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROPACE, INC. via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERISA INDUSTRY COMMITTEE (ERIC) via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · Q1
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · RR
Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues.
Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues.
BICYCLE THERAPEUTICS via LMH STRATEGIC SOLUTIONS
2026 · first_quarter · RR
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
STEALTH BIOTHERAPEUTICS INC. via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS, INC. via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROPACE, INC. via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERISA INDUSTRY COMMITTEE (ERIC) via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · fourth_quarter · Q4
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STEALTH BIOTHERAPEUTICS INC. via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS, INC. via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROPACE, INC. via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERISA INDUSTRY COMMITTEE (ERIC) via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · third_quarter · Q3
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STEALTH BIOTHERAPEUTICS INC. via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
FDA process issues. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS, INC. via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROPACE, INC. via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
Pediatric Review Reauthorization. H.R.946/S.1862 - ORPHAN Cures Act. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERISA INDUSTRY COMMITTEE (ERIC) via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via LMH STRATEGIC SOLUTIONS
2025 · second_quarter · Q2
General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RARE DISEASE COMPANY COALITION via LMH STRATEGIC SOLUTIONS
2025 · first_quarter · 1T
Issues will be pediatric review vouchers. Orphan drug tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE